Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

Ian Tracy; William Tapper; Anton Parker; Anne Gardiner; Shalal Sadullah; Guy Pratt; Adrian Copplestone; David Oscier; Oliver Giles Best

doi:10.1111/bjh.14172

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

Ian Tracy
, William Tapper
, Anton Parker
, Anne Gardiner
, Shalal Sadullah
, Guy Pratt
, Adrian Copplestone
, David Oscier
, Oliver Giles Best

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Abstract

Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...

Original language	English
Pages (from-to)	824-826
Number of pages	3
Journal	British Journal of Haematology
Volume	178
Issue number	5
DOIs	https://doi.org/10.1111/bjh.14172
Publication status	Published - Sept 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alleles Cyclin-Dependent Kinase Inhibitor p21/*genetics/*metabolism *DNA Damage Gene Expression Genotype Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics/*metabolism *Polymorphism, Genetic Polymorphism, Single Nucleotide *Signal Transduction Tumor Suppressor Protein p53/*genetics/*metabolism * tp53 *cell signalling *chronic lymphocytic leukaemia
chronic lymphocytic leukaemia
cell signalling
TP53

Access to Document

10.1111/bjh.14172Licence: In Copyright

Cite this

Tracy, I., Tapper, W., Parker, A., Gardiner, A., Sadullah, S., Pratt, G., Copplestone, A., Oscier, D., & Best, O. G. (2017). Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities. British Journal of Haematology, 178(5), 824-826. https://doi.org/10.1111/bjh.14172

@article{9b2eb15959b64d25aaed0b733d36ed42,

title = "Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities",

abstract = "Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5\% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...",

keywords = "Alleles Cyclin-Dependent Kinase Inhibitor p21/*genetics/*metabolism *DNA Damage Gene Expression Genotype Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics/*metabolism *Polymorphism, Genetic Polymorphism, Single Nucleotide *Signal Transduction Tumor Suppressor Protein p53/*genetics/*metabolism * tp53 *cell signalling *chronic lymphocytic leukaemia, chronic lymphocytic leukaemia, cell signalling, TP53",

author = "Ian Tracy and William Tapper and Anton Parker and Anne Gardiner and Shalal Sadullah and Guy Pratt and Adrian Copplestone and David Oscier and Best, \{Oliver Giles\}",

year = "2017",

month = sep,

doi = "10.1111/bjh.14172",

language = "English",

volume = "178",

pages = "824--826",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons, Inc",

number = "5",

}

Tracy, I, Tapper, W, Parker, A, Gardiner, A, Sadullah, S, Pratt, G, Copplestone, A, Oscier, D & Best, OG 2017, 'Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities', British Journal of Haematology, vol. 178, no. 5, pp. 824-826. https://doi.org/10.1111/bjh.14172

TY - JOUR

T1 - Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

AU - Tracy, Ian

AU - Tapper, William

AU - Parker, Anton

AU - Gardiner, Anne

AU - Sadullah, Shalal

AU - Pratt, Guy

AU - Copplestone, Adrian

AU - Oscier, David

AU - Best, Oliver Giles

PY - 2017/9

Y1 - 2017/9

N2 - Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...

AB - Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...

KW - Alleles Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism DNA Damage Gene Expression Genotype Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/genetics/metabolism Polymorphism, Genetic Polymorphism, Single Nucleotide Signal Transduction

KW - chronic lymphocytic leukaemia

KW - cell signalling

KW - TP53

UR - https://www.scopus.com/pages/publications/84994338301

U2 - 10.1111/bjh.14172

DO - 10.1111/bjh.14172

M3 - Letter

SN - 0007-1048

VL - 178

SP - 824

EP - 826

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this